Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Altered Chemokine Receptor Expression in CD4<sup>+</sup> T Cells: A Signature of Visceral Leishmaniasis.

Parasite immunology·2026

Same author

Comparison of CD4 T-Cell Response in Plasmodium falciparum and vivax Malaria.

The Journal of infectious diseases·2026

Same author

Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria.

JCI insight·2025

Same author

Editorial: Leishmaniasis: control and elimination, volume II.

Frontiers in cellular and infection microbiology·2025

Same author

The development and maintenance of immunity against visceral leishmaniasis.

Frontiers in immunology·2025

Same author

Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection.

EBioMedicine·2024

Search research articles

Related Experiment Video

Updated: Apr 19, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Vaccines to prevent leishmaniasis.

Rajiv Kumar¹, Christian Engwerda¹

¹Immunology and Infection Laboratory, QIMR Berghofer , Brisbane, Queensland, Australia.

Clinical & Translational Immunology

|December 16, 2014

Summary

Leishmaniasis, a parasitic disease, can be controlled by the host immune system, but a human vaccine is lacking. Research is advancing vaccine development, focusing on novel targets like the parasite hemoglobin receptor.

Area of Science:

Parasitology
Immunology
Vaccinology

Background:

Leishmaniasis is a significant parasitic disease in tropical and subtropical areas.
Host immune responses can control Leishmania parasite growth, offering protection.
Currently, no effective human vaccine exists for leishmaniasis.

Purpose of the Study:

To review current knowledge of host immunity in Leishmania infection.
To discuss recent progress in developing leishmaniasis vaccines.
To highlight a novel vaccine approach targeting the parasite hemoglobin receptor.

Main Methods:

Review of epidemiological and experimental data on leishmaniasis.
Analysis of host immune system responses to Leishmania.
Evaluation of emerging vaccine strategies and targets.

Keywords:

immunity leishmania parasites vaccines

More Related Videos

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Related Experiment Videos

Last Updated: Apr 19, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Main Results:

Understanding of protective immune mechanisms against leishmaniasis is growing.
Vaccine development is progressing, with promising new avenues.
Targeting the parasite hemoglobin receptor shows potential for a new vaccine.

Conclusions:

Effective control of leishmaniasis is possible through host immunity.
Significant advancements are being made in leishmaniasis vaccine research.
Targeting the hemoglobin receptor represents a promising strategy for future vaccines.